公开(公告)号：US20150266944A1

公开(公告)日：2015-09-24

申请号：US14439435

申请日：2013-10-30

Applicant: BIOGEN IDEC MA INC.

Inventor： Haiyan Jiang ,  Srividya Neelakantan ,  Ivan Nestorov ,  Shuanglian Li

IPC: C07K14/755

CPC classification number: C07K14/755 ,  A61K38/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: The present invention provides methods of reducing or decreasing the annualized bleeding rate of a human subject having hemophilia by administering a long acting Factor VIII polypeptide. The long-acting FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia. The present invention relates generally to the field of therapeutics for hemostatic disorders.

Abstract translation: 本发明提供通过施用长效因子VIII多肽来降低或降低具有血友病的人类受试者的年化出血率的方法。 长效FVIII多肽可用于个体预防，每周预防，发作（按需）治疗或血友病围手术期管理。 本发明一般涉及止血障碍治疗领域。